Regeneron names new SVP portfolio management

TARRYTOWN, N.Y. — Regeneron Pharmaceuticals announced Wednesday the addition of Dr. Jay Markowitz to its leadership team as its new SVP portfolio management. He joins the pharma company from Capital World Investors, where was a U.S. pharmaceutical and biotechnology analyst and portfolio manager. 

 

“Jay is a powerful addition to our leadership team at a very important time for the company as our pipeline continues to grow and diversify," Regeneron president and chief scientific officer Dr. George Yancopoulos said. “Jay's deep scientific and medical expertise, coupled with his incredible track record as a leading biopharma portfolio manager and analyst, will help Regeneron further refine our portfolio strategy in order to bring important new medicines to patients as quickly and efficiently as possible."

 

Markowitz will work with other scientific and development leaders to evaluate the company’s portfolio evaluation and decision making while assessing external opportunities. Before Capital World Investors, Markowitz was a biotechnology analyst and portfolio manager at T. Rowe Price. Before his investment career, he was an assistant professor and transplant surgeon at Johns Hopkins University School of Medicine. 

 

"Regeneron stands out as a company with a robust, diverse pipeline and a deep productive scientific and technological engine," Markowitz said. "I am thrilled to join this great team that is advancing important and promising potential treatments for people with a number of serious diseases."